Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Novel biomarkers for cancer diagnosis and therapy selection are urgently needed to facilitate early detection and improve therapy outcomes. We have previously identified a novel phosphorylation site at serine 506 (PS506) on topoisomerase-I (topo-I) and have shown that it is widely expressed in cell...
Main Authors: | Ming Zhao, Ruth A Gjerset |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4527781?pdf=render |
Similar Items
-
CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.
by: Keya Bandyopadhyay, et al.
Published: (2012-01-01) -
The p14ARF alternate reading frame protein enhances DNA binding of topoisomerase I by interacting with the serine 506-phosphorylated core domain.
by: Keya Bandyopadhyay, et al.
Published: (2013-01-01) -
Topoisomerase I as a Biomarker: Detection of Activity at the Single Molecule Level
by: Joanna Proszek, et al.
Published: (2014-01-01) -
Study of novel dual topoisomerase poisons as potential anti-cancer drugs
by: Lewis, Louisa Joy
Published: (2005) -
Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents.
by: Raffaella Cincinelli, et al.
Published: (2018-01-01)